Tamara Springberg
Physician Assistant · Grand Rapids, MINPI 1699707380
Payments from drug & device makers
Across 25 payments — averaging $75.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$404
- Lilly USA, LLC$319
- Sanofi-aventis U.S. LLC$274
- BETA Bionics, Inc.$167
- Sequel Med Tech, LLC$155
- Amgen$125
- plus $435 from 5 others
What the payments were for
- Food & beverage$1,84998%
- Education$312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $404 |
| Lilly USA, LLC | 4 | $319 |
| Sanofi-aventis U.S. LLC | 3 | $274 |
| BETA Bionics, Inc. | 2 | $167 |
| Sequel Med Tech, LLC | 2 | $155 |
| Amgen | 1 | $125 |
| Insulet Corporation | 1 | $125 |
| Novo Nordisk | 1 | $121 |
| Dexcom, Inc. | 5 | $88 |
| Abbott | 1 | $83 |
| Boehringer Ingelheim | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$443
- MINIMED 780G$246
- MOUNJARO$234
- iLet Insulin Infusion Kit Inset$148
- iLet Insulin Infusion Kit Contact Detach$148
- TWIIST$146
- TEPEZZA$125
- Omnipod$125
- Ozempic$121
- TOUJEO$118
- Signia$107
How this compares
$1,880 in reported general payments places this provider in the 80th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 315 | $377,448 |
| OzempicSemaglutide | 119 | $183,744 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 133 | $173,684 |
| TrulicityDulaglutide | 116 | $165,325 |
| JardianceEmpagliflozin | 129 | $161,750 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 113 | $57,189 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $57,053 |
| FarxigaDapagliflozin Propanediol | 46 | $49,062 |
| Humalog Kwikpen U-100Insulin Lispro | 130 | $46,357 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $43,695 |
| Novolog FlexpenInsulin Aspart | 90 | $32,044 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $30,252 |
| HumalogInsulin Lispro | 75 | $29,456 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $28,461 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 147 | $27,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $319 | $572,228506 claims |
| Novo NordiskOzempic | $121 | $183,744119 claims |
| Boehringer IngelheimJardiance | $19 | $161,750129 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $274 | $33,83238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Grand Rapids
- Erin van DykeGrand Rapids$346K
- Melissa JosephGrand Rapids$82K
- Matthew SchultzGrand Rapids$49K
- Shannon ToddGrand Rapids$32K
- Patrick HandlinGrand Rapids$28K
- John MulderGrand Rapids$27K
- Ginger BiesbrockGrand Rapids$25K
- Matthew ZoetemanGrand Rapids$23K
- Aaron ZarnoskyGrand Rapids$22K
- Sarang PatelRoyal Oak$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.